The CIR cells are HLA-A,B null cells (HLA-C; weakly positive). The C1R-A24 cells are the C1R cells transfected with HLA-A*2402 gene. The C1R and C1R-A24 cells were kindly provided by Dr Takiguchi (University of Kumamoto, Japan). HT29(HLA-A24/1), colon carcinoma cell line, and NKN45(HLA-A24/24), gastric carcinoma cell line, were provided by Takara Shuzo Co, Ltd. (Otsu, Japan). PC9 (HLA-A24/2), lung adenocarcinoma cell line was kindly provided by Dr Yasumoto (University of Occupational and Environmental Health, Japan). These cell lines were maintained in a tissue cultureflask using RPMI 1640 supplemented with HEPES, antibiotics, and 10% heat-inactivated fetal bovine serum (FBS) (Gibco, BRL). The accumulation of p53 in all the cell lines in this study was analysed using immunohistochemistry. The p53 was accumulated in HT29, PC9 and C1R-A24 cells. However, expression of p53 was not detected in MKN45, and TISI cells. The mutation-analysis of p53 (exons 5-8) was performed on HT29, MKN45, PC9, C1R-A24 and TISI cell lines using single strand conformation polymorphism (SSCP) and direct sequence analysis. These results are summarized in Table 1 .
Synthesis of p53-derived peptides
Peptides were synthesized according to the standard solid phase synthesis method and purified by reversed phase high performance liquid chromatography (HPLC). The purity (>97%) and the identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively. Peptides were dissolved in dimetilsulphoxide (DMSO) at 20 mg ml -1 and stored at -30˚C.
MHC binding assay by flowcytometry
The binding affinity of the peptides for HLA-A24 molecules was examined using C1R-A24 cells. A total of 1 × 10 6 cells were washed 2 times in phosphate buffered saline (PBS) to remove contaminating calf serum proteins. Peptides binding to HLA-A24 molecules on C1R-A24 were stripped by mild acid treatment with an ice cold citrate phosphate buffer (0.131 M citric acid and 0.066 M Na 2 HPO 4 ) (Stomkus et al, 1993) . The buffer was adjusted to pH 3.3 with 5N NaOH or 5N HCl; this pH is essential for optimal elution of bound peptides and reconstitution of MHC class 1 molecule with the exogenously added peptides. Two millilitres of citrate phosphate buffer were added, and cell pellets were resuspended with gentle hand rocking for 60 s. Immediately after incubation, the eluted cells were buffered with a cold serum-free medium, and washed twice. Residual medium was removed by aspiration after the wash. To load the synthetic peptides, the C1R-A24 cells were incubated with 20 µg ml -1 of synthetic peptides for 2 h at 4˚C. After the washing, the expression levels of MHC class 1 molecules were determined by flowcytometric analysis using an anti class 1 antibody (W6/32) (Immunotec, Marseille, France).
Primary CTL induction cultures
Monocyte-derived DCs were used as antigen-presenting cells (APC) to trigger CTL responses using an MHC binding peptide. DCs were generated in vitro as described previously (Romani et al, 1994 ) (Romani and Gruner, 1994; Nukaya et al, 1999) . Briefly, PBMCs isolated from a normal volunteer (HLA-A24) by FicollPaque (Pharmacia, Piscataway, NJ) were separated by adherence to a plastic tissue culture flask to enrich the monocyte fraction. The monocyte-enriched population was then cultured in the presence of 1000 U ml -1 of granulocyte macrophage colony stimulating factor (GM-CSF) (Genzyme) and 2000 U ml -1 IL-4 (Genzyme) in RPMI 1640 containing HEPES and supplemented with 2 mM of L-glutamine, 1 mM of sodium pyruvate and 0.1 mM of non-essential amino acid solution, 5% heat-inactivated AB human serum (HS) (all reagents from BioWhittakar, Walkersville, MD), and antibiotics (RPMI/5% HS). After 7 days in the culture, generated DC was pulsed with 40 µg ml -1 of MHC-binding peptides in the presence of 3 µg ml -1 of β 2 -microglobulin for 4 h at 20˚C in phosphate-buffered saline (PBS) containing 1% bovine serum albumin. The peptide-pulsed DC was then irradiated (5500 rad) and mixed at a 1:20 ratio with autologous CD8 + T cells, obtained by positive selection using Dynabeads M-450 CD8 (Dynal, Lake Success, NY) and Detachabead (Dynal) following manufacturer's protocol. These cultures were set up in 48-well plates; each well contained 0.25 × 10 5 peptide-pulsed DC, 5 × 10 5 CD8 + cells and 10 ng ml -1 IL-7 (Genzyme) in 0.5 ml of RPMI/5% HS. One day later, the CTL cultures were supplemented with IL-10 (R&D Systems, Minneapolis, MN) to a final concentration of 10 ng ml -1 . On days 7 and 14, the T cell cultures were restimulated with autologous peptide-pulsed adherent APC. To prepare the adherent APC, 2 × 10 6 irradiated autologous PBMC in 0.5 ml of RPMI/5% HS was added to each well of 48-well plates. After incubation at 37˚C for 90 min, the non-adherent cells were washed off, and the adherent cells were incubated for 2 h with 20 µg ml -1 of peptide and 3 µg ml -1 β 2 -microglobulin in a final volume of 0.25 ml of RPMI/5% HS per well. Supernatants of the responder cultures were aspirated and RPMI/5% HS was added to the total volume of 0.5 ml well -1 . After removing the un-loaded peptide from the wells of adherent APC, the responder cultures were transferred to the corresponding wells containing peptide-pulsed APC. Each well was restimulated separately and on the day following each restimulation, a final concentration of 10 ng ml -1 of IL-10 was added to each culture. The cultures were fed every 2-3 days with RPMI/5% HS containing 10 U ml -1 of IL-2 (Shionogi, Osaka, Japan). Cytotoxic activity was tested after 2 and 4 rounds of peptide stimulation on days 21 and 36 using peptide-pulsed TISI cells. Responder cells in positive wells for peptide killing were expanded as described below and tested for their cytotoxity.
CTL assay
The tumour cells used as targets in the cytotoxicity assays were cultured as described previously in the presence of IFN-γ (100 U ml -1 ) to enhance the expression of MHC class 1 molecules. The TISI Cr (Daiichi Kagaku Yakuhin, Tokyo, Japan) per 3 × 10 6 cells for 1 h at 37˚C. Peptide-pulsed targets were prepared by incubating the cells at 5 × 10 5 cells ml -1 with 10 µg ml -1 of the peptide for 16 h at 37˚C. Target cells were washed by centrifugation and mixed with effectors in a final volume of 0.2 ml in roundbottom microtitre plates. The plates were centrifuged (2 min at 400 g) to increase cell-to-cell contact and placed in a CO 2 incubator at 37˚C. After 4 h of incubation, 0.1 ml of the supernatant was collected from each well and radioactivity was determined in a gamma counter. To minimize non-specific lysis due to NK-like effectors, the 10 -30 fold excess of unlabelled K562 cells were added. The MHC restriction was examined by testing the inhibition of the cytotoxicity by anti HLA-class I MAbs W6/32 and anti HLAclass II MAbs L243 and anti CD8 (Immunotec, Marseille, France). Cold target inhibition experiments utilized using unlabelled C1R cells and C1RA24 cells for completion for the recognition of 51 Crlabelled HT29 tumour cells.
The percentage of specific cytotoxicity was determined by calculating the percentage of specific 51 Cr-release by the following formula: [(cpm of the test sample release -cpm of the spontaneous release)/(cpm of the maximum release -cpm of the spontaneous release)] × 100. The spontaneous release was determined by incubating the target cells alone in the absence of effectors, and the maximum release was obtained by incubating the targets with 1 N HCl. All determinants were done in triplicate, and the standard deviation error was consistently below 10% of the mean value (Nukaya et al, 1999) .
Procedure of CTL expansion
To obtain sufficient cell numbers for detailed characterization, CTL lines were expanded in tissue cultures following methods similar to the ones described by Walter et al (Walter, 1995; Salgauer et al, 1996; Nukaya et al, 1999) . A total of 5 × 10 4 CTL were resuspended in 25 ml of RPMI/5% HS with 25 × 10 6 irradiated (3300 rads) PBMC and 5 × 10 6 irradiated (8000 rads) Epstein-Barr virus-transformed β-lymphoblastoid cell line EHM cells (HLA-A3/3) in the presence of 30 ng ml -1 of anti-CD3 MAb. One day after initiating the cultures, 120 IU ml -1 of IL-2 was added to the cultures. The cultures were fed with fresh RPMI/5% HS containing 30 IU ml -1 of IL-2 on days 5, 8 and 11 and were split if the T-cell concentration reached numbers >1.5 × 10 6 ml -1
. On average, approximately 1-2 × 10 7 CTLs were obtained by days 12-14.
RESULTS

HLA-A24 binding peptides from the murine p53 cytotoxic peptides
To identify the potential epitope peptides of murine p53, the sequence of murine p53 were examined for the presence of specific MHC binding motifs for the H-2K d and H-2K b as examined for specific HLA-A alleles (Celis et al, 1994) . 3 peptides were selected based on the high-binding motifs as shown in Table 2 , that is, p53-137 (amino acids, 137-148) (Yaruck et al, 1993) , p53-161 (161-169) (Vierboom et al, 1997) , and p53-235 (235-243) (Mayordomo et al, 1996) . These peptides were synthesized and their binding affinities were analysed by HLA-A24 peptidebinding assay, using C1R-A24 cells. The C1R-A24 cell was incubated in the presence of 20 µg ml -1 of peptide for 2 h, stained with W6/32, the HLA class I specific antibody, and analysed with flowcytometry. Expression level of the MHC class I molecules was significantly higher than the negative control when p53-137 or p53-161 was pulsed (142 of mean channels in the p53-161 peptide pulsed cells, 115 in the p53-137, whereas 100 in the non peptide-pulsed cells). These results indicate that 2 predicted peptides had HLA-A24 binding affinities.
CTL induction
The p53-161 and p53-137 peptides were studied for their capacity to induce CTL in vitro. To examine this question, PBMCs from 6 HLA-A24 + healthy donors were stimulated using DCs pulsed with synthetic peptides. The p53-161 peptide induced tumour-specific CTL in 2 of the 4 donors. However, the p53-137 peptide did not induce tumour-specific CTL. After 4 rounds of restimulation, these CTLs that lysed peptide-pulsed target cells were expanded using anti-CD3 MAb and a mixture of feeder cells for further analysis. Peptide specific CTL responses were measured in a 4 h 51 Cr releasing assay (CRA) using peptide-pulsed TISI cells as targets. As shown in Figure 1 , the CTL raised against p53-161 (line 41) efficiently lysed TISI cells only when they were pulsed with p53-161 peptide. Furthermore, the p53-specific CTL lines lysed the various cell lines which have p53 overexpression with HLA-A24. The tumour lines, pretreated with 100 U ml -1 of IFNγ for 48 h, and non-labelled (cold) K562 cells were added to target populations. HT29 (colon carcinoma, p53 + , HLA-A24 
Characterization of the established CTLs
To examine the characteristics of CTL lines raised against p53 peptide, MAbs against HLA class I MAb, HLA class II MAb, CD8 were tested for their capacity to inhibit the cytotoxic activity. The cytotoxicity of CTL against the HT29 targets was significantly reduced when anti class I and anti CD8 MAb were used, indicating that the CTL lines recognize the p53 derived peptide in an HLA class I restricted manner (Figure 3) . Furthermore, the CTL lysed C1R-A24 (p53 + , HLA-A*2402 transfectant) cells, but not their parent cell lines C1R (p53 + , HLA A, B, C null cell) (Figure 4) . These results clearly indicate that the cytotoxic activity of the CTLs is HLA-A*2402 in a restricted manner. Cold target inhibition experiments were performed using unlabelled C1R cells and C1R-A24 cells to examine the specificity of CTL recognizing HT29 tumour cells. The cytotoxicity against the HT29 cells was suppressed with the cold C1R-A24 cells but not with C1R cells (Figure 5 ). Thus, these results strongly suggest that the CTL lines raised against p53-161 recognize p53-derived epitopes in HLA-A*2402 restricted fashion.
DISCUSSION
Tumour antigens, which are specifically presented by a class I MHC molecules on the multiple types of tumours, are very good candidates for cancer vaccine (Harris, 1996) . However, most of the TAAs currently available are expressed on specific tumour types (Salgaller et al, 1996; Lee et al, 1999) , and most of the epitope peptides identified are restricted to HLA-A2 allele (Butterfield et al, 1999; Vissers et al, 1999) . This situation limits the broad applicability of this approach. To improve the situation, efforts have been made to identify TAAs expressed in multiple cell types (van den Burg et al, 1995; Tanaka et al, 1997; Fujie et al, 1999; Kikuchi et al, 1999; Oiso et al, 1999) . As the same time, new tumour antigenic peptides restricted to other HLA class I alleles have been explored (van den Burg et al, 1996; Nestle et al, 1998; Maric and Liu, 1999; Wang et al, 1999; Yang et al, 1999) . Mutant p53 is expressed in 50% of malignant tumours. Especially gastrointestinal carcinomas, which are the common cancers in the Asian region, mutation of p53 is observed more frequently when compared with that observed in tumours of other types. The spectrum of p53 mutations is very wide and variable (Harris, 1996) . However, most mutation in p53 is a single base missense-mutation confirmed in specific regions. Thus, some of the wild-type epitopes outside of the area are maintained in many cases. Wild-type p53 may be ignored by the immune system due to insufficient amounts and extremely short t 1/2 (Gnjatic et al, 1998) . Mutated p53 would become immunogenic due to the stabilization and the accumulation in tumour cells. Therefore, the epitopes found in the conserved area of the wild-type p53 could serve as immunologic targets in various tumour types.
The idea that p53 can serve as a target for immunotherapy has been explored in the past (Zhou et al, 1999; Hernandez et al, 2000) , and antigenic p53 peptides restricted by HLA-A2 have been described. However, the antigenic peptides restricted to HLA-A24 allele, most of which (90%) is HLA-A*2402 subtype and frequency (60%) expressed in Asians including Japanese (Nukaya et al, 1999) . Thus, we have tried to identify a new p53 epitope peptide presented by HLA-A24.
In this study, we obtained the evidence that p53-161, nonamer peptide derived from wild-type p53, induces CTL in vitro. The induced CTL line showed specific cytotoxicity not only against the peptide-pulsed target cells but also against HLA-A24-positive adenocarcinoma cell lines overexpressing p53. Because the wildtype p53 is normally ignored by the immune system due to its short half-life, this response is not so much recognition of endogenously processed with wild-type p53 in MKN45 cell or TISI cell as bulk CTL response. However, Ropke et al, reported that the accumulation of mutated p53 protein was not absolute requirement for killing by p53-specific CTL (Ropke et al, 1996) . The relation between presentation of p53 epitope and recognition by p53 specific CTL still remains to be examined. Furthermore, these CTLs kill targets in an HLA-A24 restricted manner. These results suggest that the p53-161 peptide is one of p53 epitope peptides restricted to HLA-A24.
The P53-161 peptide (AIYKQSQHM) derived from human wild-type p53 was predicted from the epitope (AIYKKSQHM; amino acid 158-166) derived from mouse wild-type p53. The CTL, generated in p53-deficient mice and recognizing this peptide presented on H-2K b molecule was also capable of preventing the outgrowth of p53-overexpressed tumours in immunocompetent p53 (+/+) C57BL/6 mice (Vierboom et al, 1997) . Typical HLA-A24 binding motifs have Tyr or Trp at position 2 and Phe, Leu or Ileu at position 9 of a nonamer peptide. Interestingly, p53-161 has Tyr at position 3, and Met, of which affinity is lower than Phe, Leu and Ileu, at position 9 (Kubo et al, 1994) . These characteristics lead to low binding affinity of p53-161 peptide for HLA-A24 molecules. It is possible that other peptides with which high affinity could be expressed at high levels on the cell surface during initial T cell education may be deleted from the T-cell repertoire. Lower binding or subdominant determinants could have escaped this process for tolerance induction (van den Burg et al, 1995) . Similar to some of the other peptide epitopes of TAAs (Solgaller et al, 1996) , p53-161 has only one anchor residue and weak binding affinity to HLA-A24. It has been very difficult to treat the advanced and metastatic cancers with any exiting therapy including surgery, chemotherapy and radiotherapy. As the mutated p53 accumulates in most of the metastatic tumour cells, and is associated with the resistance to chemotherapy and radiotherapy, a p53-peptide-based immunotherapy could be helpful for patients with advanced cancer. Furthermore, immunization with a combination of other antigens including CEA and HER2/neu might lead to a successful outcome.
